Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups.

Authors:
Clark KEN; Xu S; Attah M; Ong VH; Buckley CD and 1 more

Journal:
Ann Rheum Dis

Publication Year: 2023

DOI:
10.1136/ard-2023-224184

PMCID:
PMC10646865

PMID:
37580109

Journal Information

Full Title: Ann Rheum Dis

Abbreviation: Ann Rheum Dis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Rheumatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests: CPD has received research grants to the institution from Servier, Horizon, Arxx Therapeutics and GlaxoSmithKline, consulting fees from Arxx Therapeutics, Roche, Janssen, GlaxoSmithKline, Bayer, Sanofi, Galapagos, Boehringer Ingelheim, CSL Behring, and Acceleron, and honoraria from Janssen, Boehringer Ingelheim, and Corbus. CDB has stocks in Mestag Therapeutics. Other authors declare that they have no competing interests."

Evidence found in paper:

"Funding: This work was funded by a research grant to UCL from GlaxoSmithKline, and Medical Research Council UK grant MR/T001631/1 (fellowship to KENC)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025